Novitas, the Medicare Administrative Contractor (MAC) for Pacific Edge's US lab, has been granted an extension to finalise or withdraw the Local Coverage Determination (LCD) for genetic testing for oncology.
This extension was confirmed by Novitas after considering feedback from interested parties.
The continued deliberation on the LCD means that Pacific Edge's Cxbladder tests, including Triage, Detect, and Monitor, will continue to receive reimbursement from Medicare and Medicare Advantage payers.
However, the company still expects Novitas to eventually finalise the LCD, although the timeframe remains unknown.
Pacific Edge will provide updates to shareholders as it gains more certainty on the status and resolution timeline of the LCD.
See more
